Unlocking the potential of molecular diagnostics to tackle antimicrobial resistance

Mobidiag is a commercial stage, fast-growing Finnish-French biotechnology company, specializing in the development and marketing of fast, reliable and cost-effective molecular innovative diagnostic solutions for  Gastrointestinal InfectionsAntimicrobial Resistance Management and Hospital Associated Infections (HAIs).

At Mobidiag, we are addressing a significant global health challenge:

  • The global demand for diagnosing infectious diseases is increasing. Diagnostic solutions available in the market today do not fully meet the current needs of clinical laboratories and the health care industry.
  • The alarming rise of antimicrobial resistance (AMR): by 2050, 10 million people could die each year due to the spread of multidrug resistant organisms ("superbacteria") and the lack of treatment available, which is more than the current rates for cancer and diabetes combined (1).
  • Traditional diagnostic methods are generally cheap but time-consuming, labour intensive and lacking in sensitivity, while new molecular diagnostic solutions are fast and easy to use, but expensive. This obvious gap in the market is the space which Mobidiag aims to fill.
  • In addition to this, infectious diseases represent a large portion of the current market given the re-emergence of infectious threats.

(1) Tackling drug-resistant infections globally: Final report and Recommendations, Review on Antimicrobial Resistance 2014-2016

The investors page aims at presenting Mobidiag achievements and performance to bring you further insights on our core business in the field of in vitro diagnostics. Feel free to browse through the available material.

If you have any questions,  contact us and we would be more than happy to discuss Mobidiag highlights with you.

Press releases

2019

04/02: Mobidiag announces completion of €10m equity investment from Autobio Diagnostics

07/01: New Novodiag CarbaR+ test allows rapid cost-effective molecular testing for superbacteria and associated drug resistance

2018

17/12: Mobidiag Announces Joint Venture with Autobio Diagnostics and €10m equity investment

15/11: Mobidiag Receives Final €4M Tranche of €15M EIB Financing

29/05: Mobidiag Secures Additional Funding From Business Finland For Development Of Rapid Sepsis Diagnostics Test Directly From Blood

24/05: Mobidiag Secures Additional €4 Million in Capital Increase with Springvest´s Public Financing Round

19/04: Mobidiag Announces Release of Amplidiag CarbaR+MCR a Multiplex PCR Test for Molecular Detection of Antibiotic Resistances

14/04: Novodiag Bacterial GE+, a new diagnostic test for on-demand detection of bacterial pathogens

05/03: Mobidiag implements high throughput manufacturing lines to answer growing needs for Novodiag cartridges

03/01: Novodiag® launch, a new diagnostic solution for infectious diseases

2017

21/12: Novodiag® launch, a new diagnostic solution for infectious diseases

23/11: Mobidiag Signs Agreement with Interlux for the Distribution of Amplidiag® Diagnostic Tests and Instruments in Estonia

26/06: Mobidiag Announces Release of Amplidiag Viral GE a Multiplex PCR Test to Detect Gastrointestinal Viruses Directly from Stool Samples

30/05: Mobidiag Extends Distribution Agreement with PerkinElmer to Offer Amplidiag Diagnostics Products in African Countries and Israel

18/04: Mobidiag Secures Additional 3,99 Million Euros from Kansalaisrahoitus’ Public Financing Round

06/04: Mobidiag Signs Agreement with AB ANALITICA for the Distribution of Amplidiag® Diagnostic Tests and Instruments in Italy

27/03: Mobidiag Pursues its Growth with New Offices in United Kingdom and Appoints Stuart Cranmer as Managing Director

15/03: Mobidiag Granted Patents Covering the Method and related Kit for Detecting Antibiotic Resistant Bacteria

23/01: Mobidiag Announces Release of Amplidiag Easy, a Proprietary Molecular extraction and PCR Setup System Allowing Automation of Multiplex PCR directly from Stool Samples

17/01: Mobidiag to Offer Amplidiag® Diagnostics Products in South Africa

2016

04/10: Mobidiag Announces Agency Agreement with YouMed for the Commercialization of its molecular diagnostic product line Amplidiag in UK

26/09: Mobidiag Signs Agreement with Bioportugal Quimica Farmaceutica Lda for Distribution of Amplidiag in Portugal

05/09: Mobidiag Extends Agreement with Biomedica Medizinprodukte for Distribution of Amplidiag in Central and Eastern Europe

29/08: Mobidiag Announces Release of Amplidiag Stool Parasites

14/07: Mobidiag Secures 15 Million Euros from EIB to Accelerate the Launch of its Novodiag Platform and Suite of In Vitro Diagnostic Tests

23/06: Mobidiag_Announces_Distribution_Agreement_with_Isogen_Life_Science

A word from our CEO